Super-enhancer acquisition drives oncogene expression in triple negative breast cancer.
Triple Negative Breast Cancer (TNBC) is a heterogeneous disease lacking known molecular drivers and effective targeted therapies. Cytotoxic chemotherapy remains the mainstay of treatment for TNBCs, which have significantly poorer survival rates compared to other breast cancer subtypes. In addition t...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Public Library of Science (PLoS)
2020-01-01
|
| Reeks: | PLoS ONE |
| Online toegang: | https://doi.org/10.1371/journal.pone.0235343 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|